Search Results - "Kneba, M."

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial by Hallek, M, Prof, Fischer, K, MD, Fingerle-Rowson, G, MD, Fink, AM, MD, Busch, R, Mayer, J, Prof, Hensel, M, Prof, Hopfinger, G, MD, Hess, G, MD, von Grünhagen, U, MD, Bergmann, M, MD, Catalano, J, MD, Zinzani, PL, Prof, Caligaris-Cappio, F, Prof, Seymour, JF, Prof, Berrebi, A, Prof, Jäger, U, Prof, Cazin, B, MD, Trneny, M, MD, Westermann, A, Wendtner, CM, Prof, Eichhorst, BF, MD, Staib, P, MD, Bühler, A, MD, Winkler, D, MD, Zenz, T, MD, Böttcher, S, MD, Ritgen, M, MD, Mendila, M, MD, Kneba, M, Prof, Döhner, H, Prof, Stilgenbauer, S, Prof

“…Summary Background On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal…”
Get full text

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) by Hanfstein, B, Müller, M C, Hehlmann, R, Erben, P, Lauseker, M, Fabarius, A, Schnittger, S, Haferlach, C, Göhring, G, Proetel, U, Kolb, H-J, Krause, S W, Hofmann, W-K, Schubert, J, Einsele, H, Dengler, J, Hänel, M, Falge, C, Kanz, L, Neubauer, A, Kneba, M, Stegelmann, F, Pfreundschuh, M, Waller, C F, Branford, S, Hughes, T P, Spiekermann, K, Baerlocher, G M, Pfirrmann, M, Hasford, J, Saußele, S, Hochhaus, A

“…In the face of competing first-line treatment options for CML, early prediction of prognosis on imatinib is desirable to assure favorable survival or otherwise…”
Get full text

Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study by Schultheis, B, Reuter, D, Ebert, M P, Siveke, J, Kerkhoff, A, Berdel, W E, Hofheinz, R, Behringer, D M, Schmidt, W E, Goker, E, De Dosso, S, Kneba, M, Yalcin, S, Overkamp, F, Schlegel, F, Dommach, M, Rohrberg, R, Steinmetz, T, Bulitta, M, Strumberg, D

“…This randomized study was designed to investigate the superiority of gemcitabine (gem) plus nimotuzumab (nimo), an anti-epidermal growth factor receptor…”
Get full text

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008 by Brüggemann, M, Schrauder, A, Raff, T, Pfeifer, H, Dworzak, M, Ottmann, O G, Asnafi, V, Baruchel, A, Bassan, R, Benoit, Y, Biondi, A, Cavé, H, Dombret, H, Fielding, A K, Foà, R, Gökbuget, N, Goldstone, A H, Goulden, N, Henze, G, Hoelzer, D, Janka-Schaub, G E, Macintyre, E A, Pieters, R, Rambaldi, A, Ribera, J-M, Schmiegelow, K, Spinelli, O, Stary, J, von Stackelberg, A, Kneba, M, Schrappe, M, van Dongen, J J M

“…Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia…”
Get full text

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL by Rawstron, A C, Böttcher, S, Letestu, R, Villamor, N, Fazi, C, Kartsios, H, de Tute, R M, Shingles, J, Ritgen, M, Moreno, C, Lin, K, Pettitt, A R, Kneba, M, Montserrat, E, Cymbalista, F, Hallek, M, Hillmen, P, Ghia, P

“…Detection of minimal residual disease (MRD) in chronic lymphocytic leukaemia (CLL) is becoming increasingly important as treatments improve. An internationally…”
Get full text

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib by Hanfstein, B, Shlyakhto, V, Lauseker, M, Hehlmann, R, Saussele, S, Dietz, C, Erben, P, Fabarius, A, Proetel, U, Schnittger, S, Krause, S W, Schubert, J, Einsele, H, Hänel, M, Dengler, J, Falge, C, Kanz, L, Neubauer, A, Kneba, M, Stegelmann, F, Pfreundschuh, M, Waller, C F, Spiekermann, K, Baerlocher, G M, Pfirrmann, M, Hasford, J, Hofmann, W-K, Hochhaus, A, Müller, M C

“…Early assessment of response at 3 months of tyrosine kinase inhibitor treatment has become an important tool to predict favorable outcome. We sought to…”
Get full text

Improved reliability of lymphoma diagnostics via PCR-based clonality testing: - Report of the BIOMED-2 Concerted Action BHM4-CT98-3936 by VAN KRIEKEN, J. H. J. M, LANGERAK, A. W, GAULARD, P, JASANI, B, GARCIA, J. F, OTT, M, HANNSMANN, M. L, BERGER, F, HUMMEL, M, DAVI, F, BRÜGGEMANN, M, LAVENDER, F. L, MACINTYRE, E. A, SCHUURING, E, EVANS, P. A. S, WHITE, H, SALLES, G, GROENEN, P. J. T. A, GAMEIRO, P, POTT, Ch, VAN DONGEN, J. J. M, KNEBA, M, HODGES, E, GARCIA SANZ, R, MORGAN, G. J, PARREIRA, A, MOLINA, T. J, CABECADAS, J

“…The diagnosis of malignant lymphoma is a recognized difficult area in histopathology. Therefore, detection of clonality in a suspected lymphoproliferation is a…”
Get full text

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis by Böttcher, S, Stilgenbauer, S, Busch, R, Brüggemann, M, Raff, T, Pott, C, Fischer, K, Fingerle-Rowson, G, Döhner, H, Hallek, M, Kneba, M, Ritgen, M

“…Rituximab-containing regimens are becoming a therapeutic standard in chronic lymphocytic leukemia (CLL), so that a validation of flow cytometric minimal…”
Get full text

GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses by Sellner, L, Brüggemann, M, Schlitt, M, Knecht, H, Herrmann, D, Reigl, T, Krejci, A, Bystry, V, Darzentas, N, Rieger, M, Dietrich, S, Luft, T, Ho, A D, Kneba, M, Dreger, P

“…Allogeneic stem cell transplantation (alloSCT) is used for treating patients with T-prolymphocytic leukemia (T-PLL). However, direct evidence of GvL activity…”
Get full text

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia by RAWSTRON, A. C, VILLAMOR, N, EVAN, P. A. S, NATKUNAM, Y, COUTRE, S. E, AVERY, E. D, RASSENTI, L. Z, KIPPS, T. J, CALIGARIS-CAPPIO, F, KNEBA, M, BYRD, J. C, HALLEK, M. J, RITGEN, M, MONTSERRAT, E, HILLMEN, P, BÖTTCHER, S, GHIA, P, ZEHNDER, J. L, LOZANSKI, G, COLOMER, D, MORENO, C, GEUNA, M

“…The eradication of minimal residual disease (MRD) in chronic lymphocytic leukaemia (CLL) predicts for improved outcome. However, the wide variety of MRD…”
Get full text

ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology by Arends, J., Bodoky, G., Bozzetti, F., Fearon, K., Muscaritoli, M., Selga, G., van Bokhorst-de van der Schueren, M.A.E., von Meyenfeldt, M., Zürcher, G., Fietkau, R., Aulbert, E., Frick, B., Holm, M., Kneba, M., Mestrom, H.J., Zander, A.

“…Enteral nutrition (EN) by means of oral nutritional supplements (ONS) and tube feeding (TF) offers the possibility of increasing or ensuring nutrient intake in…”
Get full text

Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia by Fürstenau, M., Bahlo, J., Fink, A. M., Lange, E., Dreger, P., Dreyling, M., Hess, G., Ritgen, M., Kneba, M., Döhner, H., Stilgenbauer, S., Wendtner, C. M., Goede, V., Fischer, K., Böttcher, S., Hallek, M., Eichhorst, B.

Get full text

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 by VAN DONGEN, J. J. M, LANGERAK, A. W, VAN KRIEKEN, Jhjm, DROESE, J, GONZALEZ, D, BASTARD, C, WHITE, H. E, SPAARGAREN, M, GONZALEZ, M, PARREIRA, A, SMITH, J. L, MORGAN, G. J, BRÜGGEMANN, M, KNEBA, M, MACINTYRE, E. A, EVANS, Pas, HUMMEL, M, LAVENDER, F. L, DELABESSE, E, DAVI, F, SCHUURING, E, GARCIA-SANZ, R

“…In a European BIOMED-2 collaborative study, multiplex PCR assays have successfully been developed and standardized for the detection of clonally rearranged…”
Get full text

Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) by Thuss-Patience, P.C., Hofheinz, R.D., Arnold, D., Florschütz, A., Daum, S., Kretzschmar, A., Mantovani-Löffler, L., Bichev, D., Breithaupt, K., Kneba, M., Schumacher, G., Glanemann, M., Schlattmann, P., Reichardt, P., Gahn, B.

“…This prospective multicentre phase II trial assessed the feasibility and efficacy of perioperative chemotherapy with docetaxel, cisplatin and capecitabine…”
Get full text

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) by Buske, C, Hoster, E, Dreyling, M, Eimermacher, H, Wandt, H, Metzner, B, Fuchs, R, Bittenbring, J, Woermann, B, Hohloch, K, Hess, G, Ludwig, W-D, Schimke, J, Schmitz, S, Kneba, M, Reiser, M, Graeven, U, Klapper, W, Unterhalt, M, Hiddemann, W

“…Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition…”
Get full text

The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients by Kellner, C, Zhukovsky, E A, Pötzke, A, Brüggemann, M, Schrauder, A, Schrappe, M, Kneba, M, Repp, R, Humpe, A, Gramatzki, M, Peipp, M

Get full text

Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse by Hahn, M, Böttcher, S, Dietrich, S, Hegenbart, U, Rieger, M, Stadtherr, P, Bondong, A, Schulz, R, Ritgen, M, Schmitt, T, Tran, T H, Görner, M, Herth, I, Luft, T, Schönland, S, Witzens-Harig, M, Zenz, T, Kneba, M, Ho, A D, Dreger, P

“…To elucidate factors contributing to the effectiveness of allogeneic hematopoietic stem cell transplantation (alloHCT) in high-risk CLL, immune interventions,…”
Get full text

Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936 by BRÜGGEMANN, M, WHITE, H, TIEMANN, M, HERBST, H, LANGERAK, A. W, SPAARGAREN, M, MOREAU, E, GROENEN, P. J. T. A, SAMBADE, C, FORONI, L, CARTER, G. I, HUMMEL, M, GAULARD, P, BASTARD, C, DAVI, F, DELFAU-LARUE, M.-H, KNEBA, M, VAN DONGEN, J. J. M, BELDJORD, K, MOLINA, Tj, GARCIA-SANZ, R, GAMEIRO, P, OESCHGER, S., JASANI, B, OTT, M, DELSOL, G, ORFAO, A

“…Polymerase chain reaction (PCR) assessment of clonal T-cell receptor (TCR) and immunoglobulin (Ig) gene rearrangements is an important diagnostic tool in…”
Get full text

Health-related quality of life (HR-QoL) in elderly soft tissue sarcoma (STS) patients from the randomized phase II EPAZ study comparing pazopanib (PAZ) and doxorubicin (DOX) in first line by Grünwald, V., Schuler, M., Schöffski, P., Kopp, H.-G., Bauer, S., Kasper, B., Lindner, L.H., Chemnitz, J.M., Crysandt, M., Stein, A., Steffen, B., Richter, S., Kneba, M., Egerer, G., Zimmermann, S., Karch, A., Kunitz, A.

Get full text

Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial by Edelmann, J, Tausch, E, Landau, D A, Robrecht, S, Bahlo, J, Fischer, K, Fink, A M, Bloehdorn, J, Holzmann, K, Böttcher, S, Werner, L, Kneba, M, Gribben, J G, Neuberg, D S, Wu, C J, Hallek, M, Döhner, H, Stilgenbauer, S

Get full text